On March 20, the groundbreaking virtual conference "In Vivo Frontiers: The Promise and Progress of RNA Delivery & Gene Editing," hosted by the Stanford Healthcare Innovation Lab in collaboration with Fapon, took place successfully. Distinguished speakers, including Nobel Prize Winner Jennifer Doudna and renowned scientist Robert Langer, alongside other leading experts, presented in the event.

The conference delved into the transformative potential of RNA delivery and gene editing, highlighting the latest advancements and future prospects in these rapidly evolving fields. Covering topics from the current state of CRISPR technology to innovative applications of molecular technologies and RNA therapies in the industry, the event provided attendees with valuable insights into the forefront of biotechnology.

Leveraging cutting-edge technologies and strategic partnerships, Fapon is dedicated to developing technologies to advance RNA-based therapeutics. Collaborating with leading experts such as Alexander Wesselhoeft, Fapon focuses on creating state-of-the-art platforms, including circRNA platform and a novel delivery system, to address the bottlenecks in circRNA field.

In addition to advancing circRNA technology, Fapon has established an innovative biopharma business focusing on tumors and autoimmune diseases while tapping into novel antibody drugs and fusion proteins. Moreover, Fapon places significant emphasis on Artificial Intelligence, developing innovative applications such as AI-enabled bio-molecule design and AI-driven multi-omics platforms to propel industry progress.

Looking ahead, Fapon will continue to address critical technological challenges as well as accelerate the development of diagnostics and therapeutics, ultimately shaping the future of the healthcare industry.

About Fapon

Fapon is a global leading life sciences company dedicated to providing integrated solutions and services for diagnostics, biopharma and AI-enabled diagnostics and therapeutics. Integrating a one-stop solution on raw materials, reagents and innovative open instrument platforms, the Company has grown into a leading supplier in in-vitro diagnostics. Fapon boasts advanced innovations in therapeutics technologies and AI algorithm platforms with data insights that contribute to a better and healthier world. Supported by its strong global R&D, manufacturing, sales and service network, Fapon's products have established presence in 68 countries and regions, serving more than 2,500 business partners worldwide.